Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
Outlook Therapeutics submitted an HCPCS Level II application to CMS requesting a permanent, product-specific J-code for LYTENAVA, its FDA-approved ophthalmic bevacizumab for wet AMD. A permanent J-code would streamline billing and reimbursement for U.S. retina practices, though CMS notes the code is separate from coverage and payment decisions and assignment is not guaranteed. The company remains on track for a U.S.
Key figures
- Drug Name
- LYTENAVA (bevacizumab-vikg)
- Launch timing
- U.S. commercial launch on track before year-end 2026
- Cms review cadence
- quarterly
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.